Akero Therapeutics Highlights Efruxifermin's Impact on Fibrosis In an exciting development for patients battling serious metabolic diseases, Akero Therapeutics, Inc. (NASDAQ: AKRO) has shared promising results from the Phase 2b SYMMETRY trial, which investigates the effectiveness of efruxifermin (EFX) for treating compensated cirrhosis caused by metabolic...
Continue Reading
Market Reactions to Trade Tariffs The global markets are increasingly reacting to the surge in trade tensions, particularly between large economies. The introduction of tariffs on US soybeans and other agricultural products by a major global player has raised concerns for investors and businesses alike. The latest developments on the trade front could have long-lasting...
Continue Reading
ADAR1 Capital Management Issues Open Letter to Keros Board In an important communication, ADAR1 Capital Management, the largest stockholder of Keros Therapeutics (NASDAQ: KROS), has expressed its concerns regarding the Board's handling of critical company matters. Holding approximately 13.3% of the outstanding shares, ADAR1 is advocating for a more constructive dialogue...
Continue Reading
Significant Growth in Pre-Seed Bitcoin Startup Investments Recent research conducted by Trammell Venture Partners (TVP), a prominent venture capital firm based in Austin, unveils a remarkable 767% increase in pre-seed Bitcoin startup investments since 2021. This phenomenal growth indicates a rising trend of enthusiasm surrounding Bitcoin-native ventures. Although the...
Continue Reading
Bitcoin's Recent Price Movements Recently, crypto analyst Benjamin Cowen has been closely monitoring Bitcoin's performance, particularly its movements around the key support level of $79,000. He alerts investors as Bitcoin slips below this crucial threshold, indicating potential shifts in its pricing dynamics. Cowen stresses the importance of the weekly closing price in...
Continue Reading